ReviewAnnals of surgical oncology2021
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.
Review in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Mixed Neuroendocrine Carcinoma and Adenocarcinoma in a Patient With Ileal Pouch-Anal Anastomosis.ACG case reports journal · 2026Article
- Symptom burden and outcomes among patients with early-onset versus average-onset neuroendocrine neoplasms.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Impact of Symptom Phenotype on Surgical Quality and Survival in Small-Bowel Neuroendocrine Tumours: A Quality Metrics Analysis.Journal of surgical oncology · 2026Article
- Small bowel obstruction from metastatic small intestinal neuroendocrine tumor managed solely with somatostatin analog.JCEM case reports · 2026Article
- Surgery for Gastroenteropancreatic Neuroendocrine Tumors with Synchronous Liver Metastasis.Annals of surgical oncology · 2026Article
- The Role of Primary Tumor Resection in Surgical Management of Asymptomatic Metastatic PNETs: A Retrospective Single-Center Study.Annals of surgical oncology · 2026Article
- Higher Composite Social Determinants of Health Scores Are Associated With Worse Survival in Patients With Small Bowel Neuroendocrine Tumors.Journal of surgical oncology · 2026Article
- Options and Considerations in the Management of Peritoneal Disease in Patients with Small Bowel Neuroendocrine Tumors.Current treatment options in oncology · 2025Review
- Mechanistic role of miR-375 in regulating PDPK1 to promote progression of small bowel neuroendocrine tumors: a silico analysis.Discover oncology · 2025Article
- Very good effect of rescue treatment withReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.The Journal of surgical research · 2024Article
- Article
- Surgery as a Principle and Technical Consideration for Primary Tumor Resection of Small Bowel Neuroendocrine Tumors.Annals of surgical oncology · 2024Review
- Surgical aspects of small intestinal neuroendocrine tumors.World journal of gastrointestinal surgery · 2023Review
- Article
- Multiomic sequencing of paired primary and metastatic small bowel carcinoids.F1000Research · 2023Article
- Recurrent Gastrointestinal Pseudo-obstruction Because of Well-Differentiated Duodenal Neuroendocrine Tumor.ACG case reports journal · 2022Article
- Small bowel neuroendocrine neoplasm: what surgeons want to know.Abdominal radiology (New York) · 2022Review
- Risk factors for small intestinal adenocarcinomas that are common in the proximal small intestine.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Surgical resection is the foundation for treatment of small bowel neuroendocrine tumors (SBNETs). Guidelines for surgical management of SBNETs rely on retrospective data, which suggest that primary tumor resection and cytoreduction improve symptoms, prevent future complications, and lengthen survival. In advanced NETs, improvement in progression-free survival has been reported in large, randomized, controlled trials of various medical treatments, including somatostatin analogues, targeted therapy, and peptide receptor radionuclide therapy. This review discusses important studies influencing the management of SBNETs and the limitations of current evidence regarding surgical interventions for SBNETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.